Drug Trial Radar · NCT00064753
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Last checked: Nov 19, 2026Latest source record: Oct 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,110
Actual
Start
May 2002
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Sponsor type
- NIH
- Collaborators
- Office of Dietary Supplements (ODS)
- First posted
- Jul 15, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
Conditions
- Chronic Kidney Disease
- Cardiovascular Disease
- Death
Interventions
High Dose MultivitaminDrug
Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
Low Dose MultivitaminDevice
Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrent or de Novo Arteriosclerotic Cardiovascular Disease (CVD) Defined as the Occurrence of Non-fatal or Fatal Arteriosclerotic Outcomes Including Coronary Heart, Cerebrovascular, and Peripheral Vascular Disease EventsTime frame: Up to 6 years (mean 4 years)
Locations
30 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama
Banner Good Samaritan Transplant
Phoenix, Arizona
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation
Los Angeles, California
University of California at Los Angeles
Los Angeles, California
University of California at San Francisco
San Francisco, California
Northwestern University
Chicago, Illinois
Southern Illinois University
Springfield, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Maine Medical Center
Portland, Maine
University of Maryland Medical Center
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Faireview University Medical Center
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Albany Medical Center
Albany, New York
State University of New York Downstate Medical Center
Brooklyn, New York
Duke University Medical Center
Durham, North Carolina
East Carolina University
Greenville, North Carolina
The Ohio State University Medical Center
Columbus, Ohio
Oregon Health Sciences University
Portland, Oregon
Drexel University
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
University of Wisconsin at Madison
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Universidade Federal de Sao Paulo
São Paulo, São Paulo, Brazil
London Health Sciences Center
London, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.